Nordic Nanovector ASA, established in 2009, is a privately held company based in Oslo, Norway. Our mission is to develop innovative radioimmunotherapeutics that target difficult to treat cancers using the company’s proprietary nanovector targeting technology. Nordic Nanovector intends to commercialise its product candidates through strategic alliances and partnerships with experienced oncology businesses and by establishing its own sales and marketing capabilities in selected markets.
The company’s lead product candidate, Betalutin™, is a radioimmunotherapeutic that aims to prolong and improve the quality of life of people who suffer from non-Hodgkin Lymphoma (NHL). The product candidate is currently undergoing a Phase I/II clinical trial for treatment of relapsed NHL.